Research programme: angiogenesis inhibitors - CGI Pharmaceuticals

Drug Profile

Research programme: angiogenesis inhibitors - CGI Pharmaceuticals

Alternative Names: ASKA EphB4; Cancer therapeutics - CGI Pharmaceuticals; EphB4 inhibitors - CGI Pharmaceuticals; Multiplex angiogenesis inhibitors - CGI Pharmaceuticals

Latest Information Update: 23 Sep 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CGI Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 25 Jul 2007 This programme is still in active development
  • 10 Aug 2005 Cellular Genomics is now called CGI Pharmaceuticals
  • 20 Jul 2005 CGI Pharmaceuticals has selected CGI 1842 as its lead candidate
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top